IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that company management will present an overview of the company at the following conferences in November.
-
Raymond James Fall Investor Conference
- Attendee: Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer
- Date: Tuesday, November 15, 2016
- Location: Boston, MA
-
Jefferies 2016 London Healthcare Conference
- Presenter: Richard Rubino, Chief Financial Officer
- Presentation Date: Wednesday, November 16, 2016
- Presentation Time: 1:20pm G.M.T.
- Location: London, UK
-
Stifel Nicolaus 2016 Healthcare Conference
- Presenter: Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer
- Presentation Date: Wednesday, November 16, 2016
- Presentation Time: 9:30am E.T.
- Location: New York, NY
The Jefferies 2016 London Healthcare Conference presentation and Stifel Nicolaus 2016 Healthcare Conference fireside chat discussion will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/. A replay of each webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA filing for Rhopressa™ (netarsudil ophthalmic solution) 0.02% was originally submitted in the third quarter of 2016 and is expected to be resubmitted in January 2017. The second product candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa™ and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a Roclatan™ NDA filing is expected to take place near year-end 2017. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.
